Here is the latest shareholding Pattern of BALAXI PHARMA. For more details, see the BALAXI PHARMA financial fact sheet and BALAXI PHARMA share price. For a sector overview, read our pharmaceuticals sector report.
No. of Mths Qtr. Ending |
3
Jun-22 |
3
Sep-22 |
3
Dec-22 |
3
Mar-23 |
3
Jun-23 |
3
Sep-23 |
3
Dec-23 |
3
Mar-24 |
||
---|---|---|---|---|---|---|---|---|---|---|
Indian Promoters | % | 72.86 | 72.86 | 72.69 | 71.57 | 71.22 | 71.22 | 71.22 | 66.86 | |
Foreign Promoters | % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Total Promoters | % | 72.86 | 72.86 | 72.69 | 71.57 | 71.22 | 71.22 | 71.22 | 66.86 | |
Mutual Funds | % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Financial institution/Banks/Insurance | % | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.02 | |
Government | % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
FII | % | 19.00 | 19.00 | 18.95 | 18.66 | 18.58 | 18.58 | 18.58 | 17.21 | |
Other | % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 | -0.01 | 0.00 | |
Total Institution | % | 19.03 | 19.03 | 18.98 | 18.69 | 18.61 | 18.60 | 18.60 | 17.23 | |
Bodies Corporate | % | 0.37 | 0.19 | 0.21 | 0.62 | 0.50 | 0.49 | 0.47 | 4.11 | |
Individuals | % | 6.64 | 5.00 | 5.11 | 5.95 | 6.57 | 6.62 | 6.63 | 7.43 | |
NRIs/OCBs | % | 0.19 | 0.22 | 0.27 | 0.39 | 0.39 | 0.39 | 0.39 | 0.39 | |
ADR/GDR | % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Others | % | 0.91 | 2.70 | 2.74 | 2.79 | 2.72 | 2.68 | 2.69 | 3.98 | |
Total Non-Institution | % | 8.11 | 8.11 | 8.33 | 9.75 | 10.18 | 10.18 | 10.18 | 15.91 | |
Total Public | % | 27.00 | 27.00 | 27.00 | 28.00 | 29.00 | 29.00 | 29.00 | 33.00 | |
Grand Total | % | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | |
Pledged Promoter Holding | % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Subscriber Feature |
More Trading Company Shareholding Pattern: CIPLA ZYDUS LIFESCIENCES DIVIS LABORATORIES SUN PHARMA DR. REDDYS LAB
After opening the day on positive note, Indian share markets continued the momentum as the session progressed and ended on firm footing.